Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design

Hansa Biopharma AB, a company focused on rare IgG-related immunologic conditions, has announced a partnership with Cradle. The collaboration will utilize Cradle's artificial intelligence-driven protein design and engineering platform to accelerate the development of novel immunomodulatory therapies for patients suffering from severe autoimmune diseases.

Hansa Biopharma will deploy Cradle's end-to-end platform across its discovery pipeline to design, optimize, and advance new therapeutic candidates. This partnership signifies Hansa's increasing investment in AI for drug discovery, with the company expecting the platform to enable its scientists to design and engineer better therapeutic candidates more rapidly and with a higher probability of success.

"We selected Cradle because it combines three capabilities we believe are essential for next-generation protein engineering: end-to-end support across the discovery pipeline, multi-parameter optimization across complex engineering objectives, and active learning from our own data to drive increasingly predictable outcomes," stated Sofia Järnum, VP Head of Research and Early Development at Hansa. "Cradle's platform enables Hansa scientists to design and engineer better therapeutic candidates, faster and with greater probability of success."

The partnership emerges as the biotech industry increasingly shifts toward unified AI platforms that integrate candidate generation, optimization, and continuous learning from experimental data within a single workflow. Cradle reports that its customers have achieved development timelines up to 18 months faster, suggesting significant R&D savings per clinical candidate.

Sofia Järnum, VP Head of Research and Early Development at Hansa Biopharma AB, said that they chose Cradle as it combines three capabilities they consider essential for next-generation protein engineering: end-to-end support across the discovery pipeline, multi-parameter optimization for complex engineering objectives, and active learning from their own data for more predictable outcomes. Each of these accelerates their lab-in-the-loop process. She added that Cradle's platform enables Hansa scientists to design and engineer better therapeutic candidates, faster and with a greater probability of success. Cradle is a leading provider of AI-driven protein design and engineering platform for biologics. Hansa Biopharma focuses on rare IgG-related immunologic conditions and seeks novel immunomodulatory therapies for autoimmune diseases. Hansa's lead product, imlifidase, is a first-in-class enzyme available in Europe as Idefirix and is under FDA review for kidney transplant patients. Hansa Biopharma AB is a commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies for rare and severe autoimmune diseases. Cradle offers an end-to-end protein engineering platform integrating AI-driven molecular engineering, active learning from experimental data, and multi-property optimization into a single system. Together, the companies aim to accelerate the discovery and development of novel, high-quality biologics.